Access
This article is part of Nature's premium content.
Published online 6 March 2003 | Nature | doi:10.1038/news030303-7
News
Monoclonal antibodies inhibit prion replication and delay the development of prion disease
Therapy looks best yet to tackle brain disease.
The possibility of using antibodies to treat variant Creutzfeldt-Jakob disease (vCJD) receives a boost this week, with the first promising results from an animal trial.
The lethal brain condition - which is a human version of mad cow disease - occurs when healthy proteins called prions become twisted and clump together.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
